|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4935341A
(en)
|
1986-06-04 |
1990-06-19 |
Whitehead Institute For Biomedical Research |
Detection of point mutations in neu genes
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
JPS58118008A
(ja)
|
1982-01-06 |
1983-07-13 |
Nec Corp |
デ−タ処理装置
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3483949D1
(de)
|
1983-09-26 |
1991-02-21 |
Udo Dr Med Ehrenfeld |
Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
CA1341191C
(en)
|
1988-04-18 |
2001-02-27 |
Robert Allan Weinberg |
Detection of neu gene expression and products
|
|
DE69031120T2
(de)
|
1989-05-19 |
1998-01-15 |
Genentech, Inc., South San Francisco, Calif. |
Her2 extrazellulare domäne
|
|
US5705157A
(en)
|
1989-07-27 |
1998-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of treating cancerous cells with anti-receptor antibodies
|
|
US6884418B1
(en)
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
|
ES2166352T3
(es)
|
1989-08-04 |
2002-04-16 |
Schering Ag |
Dominio externo de c-erbb-2:gp75.
|
|
WO1991005264A1
(en)
|
1989-09-29 |
1991-04-18 |
Oncogenetics Partners |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
AU662311B2
(en)
|
1991-02-05 |
1995-08-31 |
Novartis Ag |
Recombinant antibodies specific for a growth factor receptor
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5939531A
(en)
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
|
DE69228300T2
(de)
|
1991-08-22 |
1999-09-23 |
Becton Dickinson And Co., Franklin Lakes |
Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
US5288477A
(en)
|
1991-09-27 |
1994-02-22 |
Becton, Dickinson And Company |
Method for prognosticating response to cancer therapy
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
AU3236793A
(en)
|
1991-12-12 |
1993-07-19 |
Berlex Laboratories, Inc. |
Recombinant and chimeric antibodies to c-erbB-2
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
AU4025193A
(en)
|
1992-04-08 |
1993-11-18 |
Cetus Oncology Corporation |
Humanized C-erbB-2 specific antibodies
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
AU687346B2
(en)
|
1992-06-30 |
1998-02-26 |
Oncologix, Inc. |
A combination of anti-erbB-2 monoclonal antibodies and method of using
|
|
WO1994009022A1
(en)
|
1992-10-09 |
1994-04-28 |
Oncor, Inc. |
Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
|
|
CA2103323A1
(en)
|
1992-11-24 |
1994-05-25 |
Gregory D. Plowman |
Her4 human receptor tyrosine kinase
|
|
PT616812E
(pt)
|
1993-03-24 |
2000-04-28 |
Berlex Biosciences |
Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
|
|
WO1994022478A1
(en)
|
1993-03-30 |
1994-10-13 |
The Trustees Of The University Of Pennsylvania |
PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US20030108545A1
(en)
|
1994-02-10 |
2003-06-12 |
Patricia Rockwell |
Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
|
|
US5910486A
(en)
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5846749A
(en)
|
1994-10-12 |
1998-12-08 |
The Regents Of The University Of California |
Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
|
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
EP0711565B1
(en)
|
1994-11-10 |
1998-08-26 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Inhibiting growth of leukemic cells by targeting HER-2 protein
|
|
AU4289496A
(en)
|
1994-12-02 |
1996-06-19 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
|
US5783404A
(en)
|
1995-04-13 |
1998-07-21 |
Amgen Inc. |
Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
US5977322A
(en)
|
1995-06-14 |
1999-11-02 |
The Regents Of The University Of California |
High affinity human antibodies to tumor antigens
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US5925519A
(en)
|
1996-06-03 |
1999-07-20 |
The Regents Of The University Of California |
Genetic alterations associated with prostate cancer
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
KR20060079258A
(ko)
|
1996-10-18 |
2006-07-05 |
제넨테크, 인크. |
항-ＥｒｂＢ２ 항체
|
|
US6468547B1
(en)
|
1996-10-30 |
2002-10-22 |
Uab Research Foundation |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
|
|
WO1998018489A1
(en)
|
1996-10-30 |
1998-05-07 |
The Uab Research Foundation |
Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
|
|
DE69738075T2
(de)
|
1996-11-27 |
2008-05-21 |
Genentech, Inc., South San Francisco |
Affinitätsreinigung von polypeptiden an einer protein a-matrix
|
|
CA2279547A1
(en)
|
1997-01-31 |
1998-08-06 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
US20020076695A1
(en)
|
1997-04-04 |
2002-06-20 |
Jeffrey S. Ross |
Methods for treating prostate cancer
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6358682B1
(en)
|
1998-01-26 |
2002-03-19 |
Ventana Medical Systems, Inc. |
Method and kit for the prognostication of breast cancer
|
|
US20020192211A1
(en)
|
1998-03-17 |
2002-12-19 |
Hudziak Robert M. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
WO1999048527A1
(en)
|
1998-03-27 |
1999-09-30 |
Genentech, Inc. |
Apo-2 ligand-anti-her-2 antibody synergism
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
NZ507557A
(en)
|
1998-05-06 |
2003-10-31 |
Genentech Inc |
Protein purification by ion exchange chromatography
|
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
|
EP1146789B1
(en)
|
1999-01-27 |
2009-03-18 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
|
US6333348B1
(en)
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
US6316462B1
(en)
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
|
DE60040981D1
(de)
|
1999-05-14 |
2009-01-15 |
Genentech Inc |
BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
|
|
JP3485252B2
(ja)
|
1999-06-16 |
2004-01-13 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
ES2282120T3
(es)
|
1999-06-25 |
2007-10-16 |
Genentech, Inc. |
Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
|
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
BR0012196A
(pt)
|
1999-06-25 |
2002-03-19 |
Genentech Inc |
Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
|
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
|
GB9917012D0
(en)
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
|
MXPA02000962A
(es)
|
1999-07-29 |
2002-07-02 |
Medarex Inc |
Anticuerpos monoclonales humanos para her2/neu.
|
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ＥｒｂＢ2 항체 투여 치료 방법
|
|
AU7710300A
(en)
|
1999-09-22 |
2001-04-24 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
|
AU2001227966A1
(en)
|
2000-01-20 |
2001-07-31 |
Chiron Corporation |
Methods for treating tumors
|
|
JP2003525252A
(ja)
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
US6767541B2
(en)
|
2000-03-20 |
2004-07-27 |
The Regents Of The University Of California |
HER-2/neu overexpression abrogates growth inhibitory pathways
|
|
WO2001076630A1
(en)
|
2000-04-06 |
2001-10-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Diagnostics and remedies for rheumatoid arthritis
|
|
GB0008368D0
(en)
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
EA005931B1
(ru)
|
2000-05-15 |
2005-08-25 |
Фармация Италия С.П.А. |
Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты
|
|
CA2407556C
(en)
|
2000-05-19 |
2011-06-21 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
GB0017635D0
(en)
|
2000-07-18 |
2000-09-06 |
Pharmacia & Upjohn Spa |
Antitumor combined therapy
|
|
TWI317285B
(en)
|
2000-07-28 |
2009-11-21 |
Dainippon Sumitomo Pharma Co |
New use and kit for remedies for cancer
|
|
WO2002011677A2
(en)
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
|
US6602670B2
(en)
|
2000-12-01 |
2003-08-05 |
Response Genetics, Inc. |
Method of determining a chemotherapeutic regimen based on ERCC1 expression
|
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
|
US7005278B2
(en)
|
2001-03-02 |
2006-02-28 |
Danenberg Kathleen D |
Method of determining dihydropyrimidine dehydrogenase gene expression
|
|
NZ546252A
(en)
|
2000-12-01 |
2008-03-28 |
Response Genetics Inc |
Method of determining HER2-neu gene expression in paraffin embedded tissue samples
|
|
US20020142328A1
(en)
|
2000-12-01 |
2002-10-03 |
Danenberg Kathleen D. |
Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
|
|
WO2002045653A2
(en)
|
2000-12-08 |
2002-06-13 |
Uab Research Foundation |
Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
|
|
KR100983997B1
(ko)
|
2001-01-09 |
2010-09-28 |
메르크 파텐트 게엠베하 |
수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
|
|
US20040138160A1
(en)
|
2001-04-27 |
2004-07-15 |
Kenichiro Naito |
Preventive/therapeutic method for cancer
|
|
EP1385546A1
(en)
|
2001-05-08 |
2004-02-04 |
MERCK PATENT GmbH |
Combination therapy using anti-egfr antibodies and anti-hormonal agents
|
|
ITRM20010408A1
(it)
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
US7662374B2
(en)
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
|
US20030068318A1
(en)
|
2001-09-28 |
2003-04-10 |
O'brien Timothy |
Treatment of uterine serous papillary cancer
|
|
US20030096823A1
(en)
|
2001-11-16 |
2003-05-22 |
Beryl Asp |
Method for the treatment of cardiotoxicity induced by antitumor compounds
|
|
US20030175845A1
(en)
|
2002-03-13 |
2003-09-18 |
Kalbag Suresh M. |
Use of sulfitolysis in high performance peptide mapping
|
|
US20030190689A1
(en)
|
2002-04-05 |
2003-10-09 |
Cell Signaling Technology,Inc. |
Molecular profiling of disease and therapeutic response using phospho-specific antibodies
|
|
AU2003221684A1
(en)
|
2002-04-08 |
2003-10-27 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
|
EP2289942B1
(en)
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
ITTO20020340A1
(it)
|
2002-04-19 |
2003-10-20 |
Biother Di Contardi Gabriella |
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
|
|
US20030202973A1
(en)
|
2002-04-29 |
2003-10-30 |
Dr. George Pieczenik |
Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
|
|
EP1810034A4
(en)
|
2002-06-19 |
2008-06-25 |
Smithkline Beecham Corp |
PREDICTIVE MARKERS IN CANCER THERAPY
|
|
WO2004008099A2
(en)
|
2002-07-15 |
2004-01-22 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
|
US20040013297A1
(en)
|
2002-07-18 |
2004-01-22 |
Roger Lo |
Method for performing color gamut compression
|
|
HUE033623T2
(en)
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
|
WO2004048525A2
(en)
|
2002-11-21 |
2004-06-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
|
|
JP4609930B2
(ja)
|
2002-12-11 |
2011-01-12 |
ベンタナ・メディカル・システムズ・インコーポレーテッド |
Ｈｅｒ−２指向性治療に対する応答を予測する方法
|
|
CA2512536A1
(en)
|
2003-01-08 |
2004-07-29 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
|
ES2537631T3
(es)
|
2004-05-27 |
2015-06-10 |
The Regents Of The University Of Colorado |
Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
CA2611861C
(en)
*
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
JP4616237B2
(ja)
|
2006-11-07 |
2011-01-19 |
日本電信電話株式会社 |
シリコン化合物薄膜の形成方法
|
|
KR101523391B1
(ko)
*
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
US20100285039A1
(en)
|
2008-01-03 |
2010-11-11 |
The Johns Hopkins University |
B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
|
|
DK2644194T3
(en)
*
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
CA3253628A1
(en)
*
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|